Selin Sen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Selin Sen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Raphaëlle Klitting
Unité des Virus Émergents (UVE: Aix-Marseille Univ, Corsica Univ, IRD190, Inserm1207, IRBA) , Marseille
2 shared publications - Albin Fontaine
Affiliations Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France, Institut de Recherche Biomédicale des Armées (IRBA), Unité de virologie, Marseille, France
1 shared publication - Franck Touret
Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA), France
1 shared publication Geraldine Piorkowski
Unité des Virus Émergents, UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, INSERM 1207, IRBA
1 shared publicationGilda Grard
Unité des Virus Émergents (Aix-Marseille Université, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
1 shared publicationGuillaume André Durand
Unité des Virus Émergents (Aix-Marseille Université, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France
1 shared publication
Latest Publications
- Open Access
Dengue virus outbreak in Cochabamba, Bolivia
With Aedes aegypti expanding to higher altitudes, dengue virus (DENV) cases soared to record levels in 2024 in Cochabamba, Bolivia (2,558 meters above sea level). Using genome sequencing, we identified at least two distinct clades of DENV-2 genotype II circulating during the outbreak.
Open AccessDengue virus outbreak in Cochabamba, Bolivia
With Aedes aegypti expanding to higher altitudes, dengue virus (DENV) cases soared to record levels in 2024 in Cochabamba, Bolivia (2,558 meters above sea level). Using genome sequencing, we identified at least two distinct clades of DENV-2 genotype II circulating during the outbreak.
- Open Access
- 9 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Genomic surveillance reveals a dengue 2 virus epidemic lineage with a marked decrease in sensitivity to Mosnodenvir
Dengue fever is the most important arbovirosis for public health, with more than 5 million cases worldwide in 2023. Mosnodenvir is the first anti-dengue compound with very high preclinical pan-serotype activity, currently undergoing phase 2 clinical evaluation. Here, by analyzing dengue virus (DENV) genomes from the 2023-2024 epidemic in the French Caribbean Islands, we show that they all exhibit mutation NS4B:V91A, previously associated with a marked decrease in sensitivity to mosnodenvir in vitro. Using antiviral activity tests on four clinical and reverse-genetic strains, we confirm a marked decrease in mosnodenvir sensitivity for DENV-2 ( > 1000 fold). Finally, combining phylogenetic analysis and experimental testing for resistance, we find that virus lineages with low sensitivity to mosnodenvir due to the V91A mutation likely emerged multiple times over the last 30 years in DENV-2 and DENV-3. These results call for increased genomic surveillance, in particular to track lineages with resistance mutations. These efforts should allow to better assess the activity profile of DENV treatments in development against circulating strains.
- 9 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Open AccessGenomic surveillance reveals a dengue 2 virus epidemic lineage with a marked decrease in sensitivity to Mosnodenvir
Dengue fever is the most important arbovirosis for public health, with more than 5 million cases worldwide in 2023. Mosnodenvir is the first anti-dengue compound with very high preclinical pan-serotype activity, currently undergoing phase 2 clinical evaluation. Here, by analyzing dengue virus (DENV) genomes from the 2023-2024 epidemic in the French Caribbean Islands, we show that they all exhibit mutation NS4B:V91A, previously associated with a marked decrease in sensitivity to mosnodenvir in vitro. Using antiviral activity tests on four clinical and reverse-genetic strains, we confirm a marked decrease in mosnodenvir sensitivity for DENV-2 ( > 1000 fold). Finally, combining phylogenetic analysis and experimental testing for resistance, we find that virus lineages with low sensitivity to mosnodenvir due to the V91A mutation likely emerged multiple times over the last 30 years in DENV-2 and DENV-3. These results call for increased genomic surveillance, in particular to track lineages with resistance mutations. These efforts should allow to better assess the activity profile of DENV treatments in development against circulating strains.